Kamada (KMDA) Rating Increased to B at TheStreet
Several other analysts have also recently issued reports on the company. Jefferies Group reaffirmed a buy rating and set a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. Zacks Investment Research raised Kamada from a sell rating to a hold rating in a report on Wednesday, October 25th. ValuEngine raised Kamada from a sell rating to a hold rating in a report on Friday, January 5th. Chardan Capital initiated coverage on Kamada in a report on Friday, February 2nd. They set a buy rating and a $7.00 price objective on the stock. Finally, HC Wainwright reaffirmed a buy rating on shares of Kamada in a report on Thursday, February 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $7.00.
Shares of Kamada (NASDAQ KMDA) opened at $5.00 on Friday. The stock has a market capitalization of $201.31, a P/E ratio of 29.41 and a beta of 1.14. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61. The company has a current ratio of 3.30, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Paulson & CO. Inc. increased its position in shares of Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after purchasing an additional 60,000 shares during the last quarter. ARK Investment Management LLC bought a new position in shares of Kamada during the 4th quarter valued at approximately $251,000. Worth Venture Partners LLC bought a new position in shares of Kamada during the 3rd quarter valued at approximately $246,000. Navellier & Associates Inc bought a new position in shares of Kamada during the 2nd quarter valued at approximately $303,000. Finally, Analyst IMS Investment Management Services Ltd. increased its position in shares of Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after purchasing an additional 50,000 shares during the last quarter. 6.26% of the stock is currently owned by hedge funds and other institutional investors.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.